McKesson Corporation Reports Fiscal 2025 Second Quarter Results and Raises Full Year Adjusted Guidance
IRVING, Texas, November 6, 2024 - McKesson Corporation (NYSE:MCK) today announced results for the second quarter ended September 30, 2024. Second Quarter Highlights: Consolidated revenues of $93.7 b
Biologics by McKesson Named the Exclusive Pharmacy for FDA- Approved SKYCLARYS (omaveloxolone) for the Treatment of Friedreich's Ataxia
CARY, N.C., April 5, 2023 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by Reata Pharmaceuticals as the sole specialty pharmacy pr
Ontada Collaborates with Microsoft to Transform Unstructured Oncology Data with Azure OpenAI Technology
BOSTON – Oct. 17, 2024 – Ontada®, a McKesson business dedicated to oncology real-world data and evidence, clinical education, and point of care technologies, today announced that it is collaborating w
Ontada Collaborates with Microsoft to Transform Unstructured Oncology Data with Azure OpenAI Technology
BOSTON – Oct. 17, 2024 – Ontada®, a McKesson business dedicated to oncology real-world data and evidence, clinical education, and point of care technologies, today announced that it is collaborating w
InspiroGene by McKesson Unveils First-of-its-Kind Report on State of the Cell and Gene Therapy Landscape, Revealing Unparalleled Optimism Amidst Complex Challenges
Interactive map visualizes care deserts in U.S.: Up to 60 million Americans in rural areas face limited access to qualified treatment centers 99% of surveyed oncologists agree that cell and gene thera